Syndecan-1: a dynamic regulator of the myeloma microenvironment. - sprookjes - yvandenbroek - TriplyDB

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

http://www.wikidata.org/entity/Q37008599

about

Proteoglycan form and function: A comprehensive nomenclature of proteoglycans Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.The mutual impact of syndecan-1 and its glycosaminoglycan chains--a multivariable puzzle.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.Tumorigenic and adhesive properties of heparanase.Heparanase enhances myeloma progression via CXCL10 downregulation.Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.Heparan sulfate proteoglycans.Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression.The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.Heparanase: busy at the cell surface.XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo Non-anticoagulant heparins and inhibition of cancer.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Heparan sulfate proteoglycans: structure, protein interactions and cell signaling.Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.Targeting syndecans: a promising strategy for the treatment of cancer.Syndecans as modulators and potential pharmacological targets in cancer progression.Mechanisms of osteolytic and osteoblastic skeletal lesions.Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells.Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells.Heparanase: From basic research to therapeutic applications in cancer and inflammation.

P2860

Q21710680-87757F3F-6189-4D3C-BC30-E98832080823 Q24647376-3943C584-1DCB-45C6-9196-07ADA4C822A3 Q27334435-97306EF6-F59F-4764-A891-26F8F59348FC Q33347864-B0288C96-A7CB-44E1-9005-721713A9C273 Q33354119-82C5C22C-A883-4318-9922-E5D1DD04DB79 Q33400076-890503AA-7FF6-4A48-B566-95F62AC195A7 Q33924987-225BA1D9-3E28-428C-AB47-4944D1A56C96 Q34137792-3631B330-4197-4BE1-9477-E693A7BA035B Q34289445-FE1493FC-ED39-4DAB-87BE-8909328BFBFB Q34398151-14D9E53E-54E4-44AB-BB04-4CA7FA8BFDF8 Q34675956-5F436EAC-53F9-4042-963E-DCC6B25BE2E0 Q34694466-65F8DD8B-6440-4FF4-B830-112F06717C44 Q35059448-5B1225FE-130C-437A-8DD9-612EFAFEACB5 Q35140763-FE23AED7-002A-452A-83CD-4A36B50655D6 Q35695593-C1546285-FF28-43ED-882F-7B8CA4E8C898 Q35741596-719AB8AB-23D2-4148-A81A-4A9B730A88FB Q35768137-A836F13C-A519-4C78-9A92-A3F94E81683A Q36245624-840FE005-8986-47CC-99B7-123F500D0CF4 Q36354021-0302021F-25B8-4161-9221-AC3458125104 Q36498218-0F1C84C3-88DE-4512-955D-EBA30EEDB5C9 Q36787608-DD8E5F73-008A-4327-8F9A-77D3E0E027BD Q36919158-8A6B524E-57EE-4837-B07B-042F01EA4CC1 Q37340304-FC572307-3FAE-4E1E-8AC5-2A6EE847FBA7 Q37371146-4EC88264-8C98-45D5-8EB8-FD85BF202747 Q37377432-DF854861-57DC-44CE-9CEB-0AAEF661E621 Q37377754-B85CA30B-D07A-4DDB-8E09-E9963C7191AD Q37379726-8B0A7093-E200-4527-8E8F-83D5330D0DDE Q37499263-E4EC7154-3E19-4E91-A54E-B0BCCCAB225F Q37590177-3E962605-7634-4A89-99DF-AB0318700BC3 Q37608433-9EE4BDB6-7D9A-49B0-8C18-690435A4C46B Q37736668-AD84274D-F55E-44E4-8EC2-F7B861A22138 Q38082795-1CC307C4-02BE-46F4-9005-AE9AC68744DE Q38189392-04248CCF-38F9-4205-8B35-777D745A25C3 Q38625793-2E7789B1-D5E0-4495-A4DA-C27DD1486AA7 Q38703298-AD1170BF-4337-468A-87D2-1E12C6C2FF20 Q38759700-2AAB447A-D286-454A-A9B8-2D45D201FF5C Q38760595-889CB90F-E43E-4E0B-B036-78CF9E7C4E5B Q41375131-05EA472C-71DB-4FA8-836B-8527CBF065B8 Q41901774-B58E00AA-36B1-4AED-BA38-8BBEA0E06FB8 Q42587945-1D45B459-C21C-47EF-9B8D-63066059424F

P2860

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

http://www.wikidata.org/entity/Q37008599

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@en

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@nl

type

label

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@en

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@nl

prefLabel

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@en

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@nl

P1433

Q37008599-9EB6A2FB-7E37-466B-8C82-B0C5367958CB

P1476

Q37008599-4889F2BC-D233-42C2-99E4-9477DC66855F

P2093

Q37008599-3014ED22-11C0-4A2A-B81B-FEBE3E69294B

Q37008599-7CB8F457-8D88-4587-B69E-24E4396C8C18

P2860

Q37008599-04A34C02-70AE-44AB-A641-517E475A23F4

Q37008599-05138BEF-85A3-42F5-B2F3-C208A98DC033

Q37008599-08DB0D56-49FA-412D-B8E2-A4FCEA79A77E

Q37008599-0D3EE785-9A56-4309-B7F7-A2CFC45B16B6

Q37008599-1262BE5E-EEC8-438D-A5CC-3B2CA47A48C2

Q37008599-12E3639D-35D1-4B43-B9DF-6C7B87EA00B2

Q37008599-14FDA200-1996-4433-B927-4D3E823F166A

Q37008599-17997033-843D-4B23-AD8E-38F125891AA0

Q37008599-17A128A2-FD21-4AF1-9C03-7E0740BE9108

Q37008599-1A36681E-59A6-4ACD-9386-E38930E162D0

P2888

Q37008599-92F3882A-BBCE-48A5-A4F0-FF74791B6ECB

P304

Q37008599-ED3DB214-EC40-4837-A76C-A939643E6A02

P31

Q37008599-C6DA5B26-C668-4753-8CDF-42243331E8D0

P356

Q37008599-C16CFE6A-4E59-47CE-9007-E92DA71933FB

P433

Q37008599-4C054B42-BA3B-4127-B9AB-DB2FA679AD0C

P478

Q37008599-8EC89F9F-928C-4A23-B861-BB33DCF93979

P577

Q37008599-BEADC2CF-5BB5-498E-9993-91C6119316E2

P5875

Q37008599-C932C066-340F-4F00-B166-15B8A85FC92E

P698

Q37008599-8AAEC029-7B24-44CA-B782-950220193361

P932

Q37008599-5BCC6417-DF2D-479B-98F3-836E925B5016

P356

S10585-007-9125-3

P1433

Clinical & Experimental Metastasis

P1476

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

@en

P2093

Ralph D Sanderson

http://www.w3.org/2001/XMLSchema#string

Yang Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Human heparanase. Purification, characterization, cloning, and expression

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis

Characterization of syntenin, a syndecan-binding PDZ protein, as a component of cell adhesion sites and microfilaments

Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1.

Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo

B lymphocytes express and lose syndecan at specific stages of differentiation

P2888

s10585-007-9125-3

P304

149-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10585-007-9125-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5820380

http://www.w3.org/2001/XMLSchema#string

P698

18027090

http://www.w3.org/2001/XMLSchema#string

P932

3633534

http://www.w3.org/2001/XMLSchema#string